Proteomics Clinical Applications

Scope & Guideline

Exploring Proteomics for Enhanced Clinical Applications

Introduction

Welcome to your portal for understanding Proteomics Clinical Applications, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1862-8346
PublisherWILEY-V C H VERLAG GMBH
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 2007 to 2024
AbbreviationPROTEOM CLIN APPL / Proteom. Clin. Appl.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPOSTFACH 101161, 69451 WEINHEIM, GERMANY

Aims and Scopes

Proteomics Clinical Applications aims to advance the field of clinical proteomics by focusing on the application of proteomic technologies to understand disease mechanisms, discover biomarkers, and improve diagnostic and therapeutic strategies. The journal covers a broad spectrum of topics within clinical proteomics, emphasizing innovation and translational research.
  1. Clinical Biomarker Discovery:
    The journal prioritizes research that identifies and validates novel biomarkers for various diseases using proteomic techniques, facilitating early detection and personalized treatment.
  2. Disease Mechanisms and Pathophysiology:
    A core focus is on elucidating the molecular mechanisms underlying diseases through proteomic analysis, contributing to a better understanding of disease pathology.
  3. Technological Advancements in Proteomics:
    The journal highlights innovative methodologies and technologies in proteomics, such as mass spectrometry, which enhance the analysis and interpretation of complex biological samples.
  4. Integration of Multi-Omics Approaches:
    Research that integrates proteomics with other omics data (genomics, metabolomics) is encouraged, providing a comprehensive view of biological systems and disease states.
  5. Clinical Applications and Therapeutic Insights:
    Studies that translate proteomic findings into clinical applications, including drug development and therapeutic strategies, are significant for the journal's scope.
The landscape of clinical proteomics is continually evolving, with several emerging themes gaining traction in recent years. These trends reflect the journal's responsiveness to new scientific developments and the increasing complexity of clinical research.
  1. Metabolomic Integration with Proteomics:
    Recent publications have increasingly focused on the integration of metabolomics with proteomics to provide a more comprehensive understanding of disease states, particularly in metabolic and degenerative diseases.
  2. Artificial Intelligence and Machine Learning Applications:
    There is a growing trend towards utilizing AI and machine learning techniques to analyze proteomic data, enhancing biomarker discovery and improving diagnostic accuracy.
  3. Personalized Medicine and Targeted Therapies:
    Research emphasizing the role of proteomics in personalized medicine is on the rise, highlighting the importance of tailored therapeutic approaches based on individual proteomic profiles.
  4. Extracellular Vesicles and Secretomes:
    Studies investigating the role of extracellular vesicles and secretomes in disease mechanisms and biomarker discovery are emerging as a prominent theme, reflecting their significance in cell communication and pathology.
  5. Focus on Chronic Diseases and Comorbidities:
    There is an increasing emphasis on understanding the proteomic landscape associated with chronic diseases and their comorbidities, such as diabetes, cardiovascular diseases, and cancer, which is essential for developing effective management strategies.

Declining or Waning

While the journal has a strong focus on various aspects of clinical proteomics, certain themes have shown a decrease in prominence or frequency in recent publications. This may reflect shifts in research priorities or emerging trends that overshadow these topics.
  1. Basic Research in Non-Clinical Settings:
    There has been a noticeable decline in papers focusing solely on basic proteomic research not directly linked to clinical applications, as the journal emphasizes translational and applied research.
  2. Single Omics Studies:
    Research centered exclusively on proteomics without integrating other omic data has become less common, suggesting a trend towards more holistic approaches in studying diseases.
  3. Proteomics in Non-Human Models:
    The focus on animal models and non-human systems is waning, with more studies concentrating on human samples and clinical relevance, reflecting a shift towards human-centric research.
  4. Historical Proteomic Techniques:
    Older methodologies that have been replaced by more advanced techniques, such as traditional 2D gel electrophoresis, are seeing reduced representation in the journal, as the field moves towards more sophisticated mass spectrometry-based approaches.
  5. General Proteomic Reviews:
    Papers that provide broad overviews of proteomics without specific clinical applications or novel insights have decreased, indicating a preference for original research and detailed case studies.

Similar Journals

Proteome Science

Exploring the Depths of Proteomic Research
Publisher: BMCISSN: Frequency: 1 issue/year

Proteome Science is an esteemed academic journal specializing in the field of proteomics, providing a platform for advanced research and discussions surrounding the structure, function, and dynamics of proteins in biological systems. Published by BMC, a reputable publisher recognized for its commitment to open-access publishing, Proteome Science has been disseminating pivotal research findings since its inception in 2003. Targeted towards researchers, professionals, and students in biochemistry and molecular biology, the journal aims to foster collaboration and innovation within the scientific community. While it currently holds a Q3 quartile ranking in both Biochemistry and Molecular Biology categories, its impactful contributions to the field are reflected in its accessibility, as evidenced by its open access policy. By embracing collaborative research methodologies and providing a platform for novel findings, Proteome Science plays a crucial role in advancing the understanding of proteomic analyses, catering to a global audience that values groundbreaking scientific discovery.

BIOLOGICAL PROCEDURES ONLINE

Empowering Researchers with Accessible Scientific Knowledge.
Publisher: BMCISSN: Frequency: 1 issue/year

BIOLOGICAL PROCEDURES ONLINE is a premier open-access journal published by BMC, dedicated to advancing the fields of biochemistry, genetics, and molecular biology. With its electronic ISSN 1480-9222 and a strong commitment to accessibility since 2009, this journal provides a vital platform for researchers and scholars to disseminate their findings and foster collaboration within the scientific community. Based in the United Kingdom, this journal has garnered an impressive reputation, achieving Q1 status in the 2023 category rankings, with notable inclusion in the Scopus rankings, placing it in the 86th percentile among 221 peer journals in the general biochemistry, genetics, and molecular biology domain. It covers a broad range of topics, ensuring coverage of the latest advancements and methodologies in biological procedures, making it an essential resource for academics, practitioners, and students alike. Researchers are encouraged to submit their innovative work and contribute to the ongoing dialogue in this dynamic and ever-evolving field.

MOLECULAR CANCER RESEARCH

Elevating Understanding of Cancer at the Molecular Level
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

MedComm

Connecting Researchers for Global Impact
Publisher: WILEYISSN: Frequency: 4 issues/year

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

Physiology and Pharmacology

Disseminating high-quality research for a healthier future.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Cancer Genomics & Proteomics

Innovating diagnostics and therapeutics with cutting-edge research.
Publisher: INT INST ANTICANCER RESEARCHISSN: 1109-6535Frequency: 6 issues/year

Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Illuminating the Pathways of Amyloid Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1350-6129Frequency: 4 issues/year

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

MASS SPECTROMETRY REVIEWS

Exploring Innovations in Analytical Chemistry
Publisher: WILEYISSN: 0277-7037Frequency: 6 issues/year

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

PROTEIN AND PEPTIDE LETTERS

Advancing molecular insights through protein and peptide research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8665Frequency: 12 issues/year

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

Journal of Pharmaceutical and Biomedical Analysis

Unraveling complexities in drug development and clinical biochemistry.
Publisher: ELSEVIERISSN: 0731-7085Frequency: 18 issues/year

The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.